Subscribe to RSS
DOI: 10.1055/a-2494-2233
Extracellular vesicles and micro-RNAs in liver disease.
Supported by: Mayo Clinic Center for Biomedical DiscoveriesSupported by: Gilead Research Scholars
Supported by: National Institute of Diabetes and Digestive and Kidney Diseases R01 DK136511
Progression of liver disease is dependent on intercellular signaling, including those mediated by extracellular vesicles (EVs). Within these EVs, microRNAs (miRNAs) are packaged to selectively silence gene expression in recipient cells for upregulating or downregulating a specific pathway. Injured hepatocytes secrete EV-associated miRNAs which can be taken up by liver sinusoidal endothelial cells (LSECs), immune cells, hepatic stellate cells (HSCs), and other cell types. In addition, these recipient cells will secrete their own EV-associated miRNAs to propagate a response throughout the tissue and the circulation. In this review, we comment on the implications of EV-miRNAs in the progression of alcohol-associated liver disease (ALD), metabolic dysfunction-associated steatohepatitis (MASH), viral and parasitic infections, liver fibrosis, and liver malignancies. We summarize how circulating miRNAs can be used as biomarkers and the potential of utilizing EVs and miRNAs as therapeutic methods to treat liver disease.
Publication History
Received: 01 October 2024
Accepted after revision: 01 December 2024
Accepted Manuscript online:
03 December 2024
© . Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor , NY 10001 New York, USA